ANI Pharmaceuticals Inc (ANIP)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	-22,212	-7,503	35,506	43,042	19,872	13,197	-10,536	-34,603	-62,665	-87,790	-82,698	-82,031	-56,058	-27,587	-20,394	-16,022	-25,962	-31,232	-27,336	-7,625
Revenue (ttm)	US$ in thousands	614,376	555,456	538,953	517,460	486,816	449,394	401,386	358,694	316,385	283,082	251,322	226,092	216,136	212,459	213,377	213,222	208,475	199,189	197,547	203,434
Pretax margin		-3.62%	-1.35%	6.59%	8.32%	4.08%	2.94%	-2.62%	-9.65%	-19.81%	-31.01%	-32.91%	-36.28%	-25.94%	-12.98%	-9.56%	-7.51%	-12.45%	-15.68%	-13.84%	-3.75%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-22,212K ÷ $614,376K
= -3.62%

The pretax margin of ANI Pharmaceuticals Inc has shown significant fluctuations over the observed periods. The margin started in negative territory, gradually worsening from March 2020 to December 2022. However, there was a notable improvement from March 2023 onwards, where the margin turned positive and displayed a consistent upward trend. This positive trend continued until December 2023, where the pretax margin reached its peak at 8.32%. Subsequently, there was a slight decline in the pretax margin in the last two observed quarters of December 2024, ending at -3.62%.

Overall, the pretax margin of ANI Pharmaceuticals Inc reflects a volatile performance, with a recent turnaround towards profitability after a prolonged period of negative margins. This improvement indicates potential operational efficiencies and cost management initiatives that may have positively impacted the company's financial performance in the latter part of the observation period.